Safety and clinical efficacy of sintilimab (anti-PD-1) in pediatric patients with advanced or recurrent malignancies in a phase I study

Safety and clinical efficacy of sintilimab (anti-PD-1) in pediatric patients with advanced or recurrent malignancies in a phase I study

Abstract The aim of this phase I study is to evaluate, for the first time, the safety and efficacy of sintilimab in pediatric patients diagnosed with advanced or recurrent malignancies. During the dose escalation phase, patients received a single intravenous infusion of sintilimab at varying doses o...

Full description

Bibliographic Details
Main Authors: Yi Que, Juan Wang, Feifei Sun, Shan Wang, Jia Zhu, Junting Huang, Zhenzhen Zhao, Li Zhang, Juan Liu, Jiaqian Xu, Zijun Zhen, Xiaofei Sun, Suying Lu, Yizhuo Zhang
Format: Article
Language:English
Published: Nature Publishing Group 2023-10-01
Series:Signal Transduction and Targeted Therapy
Online Access:https://doi.org/10.1038/s41392-023-01636-9

Internet

https://doi.org/10.1038/s41392-023-01636-9

Similar Items